Brief: Hungary Richter Says Canada Approves Vraylar For Treatment Of Bipolar Disorder
April 27 (Reuters) - Hungarian drug maker Richter says in
statement:
* HEALTH CANADA APPROVES VRAYLAR (CARIPRAZINE) FOR TREATMENT
OF
BIPOLAR DISORDER AND SCHIZOPHRENIA IN ADULTS
* VRAYLAR IS BEING DEVELOPED JOINTLY BY ABBVIE AND RICHTER
WITH
ABBVIE RESPONSIBLE FOR COMMERCIALISATION IN US, CANADA, JAPAN,
TAIWAN AND SOME LATIN AMERICAN COUNTRIES
Source text for Eikon: [https://bet.hu/newkibdata/128713830/RCH220427ER01E.pdf
]
Further company coverage: [GDRB.BU ]
(Reporting by Krisztina Than)
((Krisztina.Than@thomsonreuters.com;))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab